Cardiovascular risk in women: The cardiologist's perspective

QJM - Monthly Journal of the Association of Physicians

Volumn 93, Issue 3, 2000, Pages 135-145

  Edmunds, E ^a   Lip, G Y H ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CONJUGATED ESTROGEN; ESTROGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEDROXYPROGESTERONE; NORGESTREL; PROGESTERONE; TRIACYLGLYCEROL;

AGING; BLOOD PRESSURE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ESTROGEN THERAPY; FEMALE; HEMOSTASIS; HUMAN; ISCHEMIC HEART DISEASE; OVARIECTOMY; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEX DIFFERENCE;

EID: 0034052085     PISSN: 14602725     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (87)

1. Office of population censuses and surveys. Mortality statistics. Review of the Registrar General on deaths by cause, sex and age in England and Wales, 1995. London, HMSO, 1994.
2. Heller RF, Jacobs HS. Coronary heart disease in relation to age, sex and the menopause. Br Med J 1978; 1:472-4.
3. Khaw KT. Where are the women in studies of coronary heart disease? Br Med J 1993; 306:1145-6.
4. Wenger NK. Exclusion of the elderly and women from coronary trials. Is their quality of care compromised? JAMA 1992; 268:1460-1.
5. Wenger NK. Cardiovascular drugs: the urgent need for studies in women. J Am Med Womens Assoc 1991; 46:117-20.
6. Dittrich H, Gilpin E, Nicod P, Cali G, Henning H, Ross J. Acute myocardial infarction in women: influences of gender on mortality and prognostic variables. Am J Cardiol 1988; 62:1-7.
7. Fiebach NH, Viscoli CM, Horwitz RI. Differences between women and men in survival after myocardial infarction: biology or methodology? JAMA 1990; 263:1092-6.
8. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998; 97:1440-5.
9. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987; 257:3233-40.
10. Cashin-Hemphill L, Mack WJ, Pogoda JM, Sanmarco ME, Azen SP, Blankenhorn DH. Beneficial effects of colestipolniacin on coronary atherosclerosis. A 4-year follow-up. JAMA 1990; 264:3013-17.
11. Petticrew M, McKee M, Jones J. Coronary artery surgery: are women discriminated against? Br Med J 1993; 306:1164-6.
12. Clarke KW, Gray D, Keating NA, Hampton JR. Do women with acute myocardial infarction receive the same treatment as men? Br Med J 1994; 309:563-6.
13. Kannel WB, Hjortland MC, McNamara PM, Gordon T. Menopause and risk of cardiovascular disease; The Framingham Study. Ann Int Med 1097; 85:447-52.
14. Gordon T, Kannel WB, Hjortland MC, McNamara PM. Menopause and Coronary Heart Disease: The Framingham Study. Ann Int Med 1978; 89:157-61.
15. Colditz GA, Willett WC, Stampfer MJ, Rosner B, Speizer FE, Hennehens CH. Menopause and the risk of coronary heart disease in women. N Engl J Med 1987; 316:1105-10.
16. Wuest JH Jr, Dry TJ, Edwards JE. The degree of coronary atherosclerosis in bilaterally oophorectomized women. Circulation 1953; 7:801-9.
17. Manchester JH, Herman MV, Gorlin R. Premenopausal castration and documented coronary atherosclerosis. Am J Cardiol 1971; 28:33-7.
18. Svanberg L. Effects of estrogen deficiency in women castrated when young. Acta Obstet Gynecol Scand Suppl 1982; 106:11-15.
19. Parrish HM, Carr CA, Hall DG, King TM. Time interval from castration in premenopausal women to the development of excessive coronary atherosclerosis. Am J Obstet Gynecol 1967; 99:155.
20. Smith PG, Dol R. Late effects of x irradiation in patients treated for metropathia haemorrhagica. Br J Radiol 1976; 49:224.
21. Rosenberg L, Hennekens CH, Belanger C, Rothman KJ, Speizer FE. Early menopause and the risk of myocardial infarction. Am J Obstet Gynecol 1981; 139:47-51.
22. Isles CG, Hole DJ, Hawthorne VM, Lever AF. Relation between coronary risk and coronary mortality in women of the Renfrew and Paisley survey: comparison with men. Lancet 1992; 339:702-6.
23. Staessen JA, Ginocchio G, Thijs L, Fagard R. Conventional and ambulatory blood pressure and menopause in a prospective population study. J Human Hypertens 1997; 11:507-14.
24. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly program (SHEP). JAMA 1991; 265:3255-64.
25. Taylor RD, Corcoron AC, Page IH. Menopausal hypertension: a critical study. Am J Med Sci 1947; 213:475-6.
26. Shibata H, Matsuzaki T, Hatano S. Relationship of relevant factors of atherosclerosis to menopause in Japanese women. Am J Epidemiol 1979; 109:420-4.
27. Lindquist O. Intraindividual changes of blood pressure, serum lipids, and body weight in relation to menstrual status: Results from a prospective population study of women in Goteborg, Sweden. Prevent Med 1982; 11:162-72.
28. Weiss NS. Relationship of menopause to serum cholesterol and arterial blood pressure: the United States' Health Examination Survey of adults. Am J Epidemiol 1972; 96:237-41.
29. Staessen J, Bulpitt CJ, Fagard R, Lijnen P, Amery A. The influence of menopause on blood pressure. J Hum Hypertens 1989; 3:427-33.
30. Crane MG, Harris JJ, Winsor III W. Hypertension, oral contraceptive agents and congugated oestrogens. Ann Intern Med 1971; 74:13-21.
31. Laragh JH, Sealy JE, Ledingham JGG, Newton MA. Oral contraceptives: Renin, aldosterone and high blood pressure. JAMA 1967; 201:918-22.
32. Mackay EV, Khoo SK, Shah NA. Reproductive steroids and the circulatory system with particular reference to hypertension. Obstet and Gynecol Survey 1973; 28:155-65.
33. Lip GY, Beevers M, Beevers DG. Malignant hypertension in young women is related to previous hypertension in pregnancy, not oral contraception. QJM 1997; 90:571-5.
34. Barr DR, Russ EM, Eder HA. Protein-lipid relationships in human plasma. Am J Med 1951; 11:480-93.
35. Barr DR, Russ EM, Eder HA. Influence of oestrogen on lipoproteins in atherosclerosis. Trans Assoc Am Phys 1952; 65:102-11.
36. Furman RH, Howard RP, Norcia LN, Keaty FC. The influence of androgens, estrogens and related steroids on serum lipids and lipoproteins. Am J Med 1958; 24:80-97.
37. Miller Bass K, Newschaffer CJ, Klag MJ, Bush TL. Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med 1993; 153:2209-16.
38. Nikkila M, Pitkajarvi T, Koivula T, Lehtomaki E, Jokela H. Age-related changes and sex differences in serum lipid concentrations in health-screening subjects. Cardiovasc Risk Factors 1991; 1:204-10.
39. Hallberg L, Svanborg A. Cholesterol, phospholipids and triglicerides in plasma in 50-year-old women. Acta Med Scan 1967; 181:185-94.
40. Hjortland MC, McNamara PM, Kannel WB. Some atherogenic concomitants of menopause: the Framingham Study. Am J Epidemiol 1976; 103:304-11.
41. Shibata H, Haga H, Suyama Y, Kumagai S, Seino T. Serum total and HDL cholesterols according to reproductive status in Japanese females. J Chron Dis 1987; 40:209-13.
42. Hamman RF, Bennett PH, Miller M. The effect of menopause on serum cholesterol in American Pima Indian women. Am J Epidemiol 1975; 102:164-9.
43. Zenker G, Koltringer P, Bone G, Niederkorn K, Pfeiffer K, Jurgens G. Lipoprotein(a) as a strong indicator for cerebrovascular disease. Stroke 1986; 17:942-5.
44. Murai A, Miyahara T, Fujimoto N, Matsuda M, Kameyama M. Lp(a) lipoprotein as a risk factor for coronary heart disease and cerebral infarction. Atherosclerosis 1986; 59:369-82.
45. Lip GYH, Jones AF. Lipoprotein (a) and vascular disease: thrombogenesis and atherogenesis. Q J Med 1995; 88:529-39.
46. Lip GYH, Blann AD, Jones AF, Beevers DG. Effects of hormone-replacement therapy on hemostatic factors, lipid factors, and endothelial function in women undergoing surgical menopause: Implications for prevention of atherosclerosis. Am Heart J 1997; 134:764-71.
47. Jenner JL, Ordovas JM, Lamon-Fava S, Schaefer MM, Wilson P, Castelli WP, Schaefer EJ. Effects of age, sex, and menopausal status on plasma lipoprotein(a) levels: the Framingham Offspring Study. Circulation 1993; 87:1135-41.
48. Kannel WB, Wolf PA, Castelli WP, d'Agostino RB. Fibrinogen and risk of cardiovascular disease. JAMA 1987; 258:1183-6.
49. Stone MC, Thorpe JM. Plasma fibrinogen - a major coronary risk factor. J Roy Coll Gen Pract 1985; 35:565-9.
50. Wilhalmsen L, Svardsudd K, Korsan-Bergtsen K. Fibrinogen as a risk factor for storke and myocardial infarction. N Engl J Med 1984; 311:501-5.
51. Lip GYH. Fibrinogen and cardiovascular disorders. Q J Med 1995; 88:155-65.
52. Bonithon-Kopp C, Scarabin PY, Darne B, Malmejac A, Guize L. Menopause-related changes in Lipoproteins and some other cardiovascular risk factors. J Epidemiol 1990; 19:42-8.
53. Meade TW, Haines AO, Imeson JD, Stirling Y, Thompson SG. Menopausal status and haemostatic variables. Lancet 1983; 1:22-4.
54. Balleisen L, Bailey J, Epping PH, Schulte H, van de Loo. Epidemiological study on factor VII, factor VIII and fibrinogen in an industrial population: 1. Baseline data on the relation to age, gender, body-weight, smoking, alcohol, pill-using and menopause. Thromb Haemostasis 1985; 54:475-9.
55. Kannel WB. Metabolic risk factors for coronary heart disease in women; Perspective from the Framingham Study. Am Heart J 1987; 114:413-19.
56. Manson JE, Willett WC, Stampfer MJ, Colditz GA, Hunter DJ, Hankinson SE, Hennekens CH, Speizer FE. Body weight and mortality among women. N Engl J Med 1995; 333:677-85.
57. Garrison RJ, Kannel WB. A new approach for estimating healthy body weights. Int J Obes Relat Metab Disord 1993; 17:417-23.
58. Reducing the health consequences of smoking: 25 years of progress: a report of the Surgeon General, 1989. Rockville MD, US Department of Health and Human Services, 1989.
59. Rosenberg L, Palmer JR, Shapiro S. Decline in the risk of myocardial infarction among women who stop smoking. N Eng J Med 1990; 322:213-17.
60. Cauley JA, LaPorte RE, Kuller LH, Bates M, Sandler RB. Menopausal estrogen use, high density lipoprotein cholesterol subfraction and liver function. Atherosclerosis 1983; 49:31-9.
61. Tikkanen M, Nikkala EA, Kuusi T, Sipinen S. High density lipoprotein-2 and hepatic lipase: reciprocal changes produced by estrogen and norgestrel. J Clin Endocrinol Metabol 1982; 54:1113-37.
62. The writing group for the PEPI trial. Effect of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women; the Postmenopausal Estrogen/ Progestin Interventions Trial. JAMA 1995; 273:199-208.
63. Medical Research Council's General Practice Research Framework. Randomized comparison of oestrogen versus oestrogen plus progesterone hormone replacement therapy in women with hysterectomy. Br Med J 1996; 312:473-8.
64. Hoefler G, Harncourt F, Paschke E, Mirtl W, Pfeiffer KH, Kostner GM. Lipoprotein PP(a) a risk factor for myocardial infarction. Arteriosclerosis 1988; 8:398-401.
65. Sandkamp M, Assman G. Lipoprotein (a) in PROCAM participants and young myocardial infarction survivors. In: Scanv AM, ed. Lipoprotein(a): 25 years of progress. New York, Academic Press, 1990:205-9.
66. Soma M, Fumagalli R, Paoletti R, Meschia M, Maini MC, Crosignani P, Ghanem K, Gaubatz J, Morrisett JD. Plasma Lp(a) concentration after oestrogen and progestagen in postmenopausal women. Lancet 1991; 337:612.
67. Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and the risk of stroke and of coronary heart disease. Br Med Bull 1994:272-98.
68. Lip GYH, Beevers M, Churchill D, Beevers G. Hormone replacement therapy and blood pressure in hypertensive women. J Human Hypertens 1994; 8:491-4.
69. Kornhauser C, Malacara JM, Garay ME, Perez-Luque EL. The effect of hormone replacement therapy on blood pressure and cardiovascular risk factors in menopausal women with moderate hypertension. J Hum Hypertens 1997; 11:405-11.
70. Christiansen C, Christiansen MS, Hagen C, Stocklund KE, Transbol I. Effects of natural estrogen/gestagen and thiazide on coronary risk factors in normal postmenopausal women. Acta Obstet Gynecol Scand 1981; 60:407-12.
71. von Eiff AW, Plotz EJ, Beck KJ, Czernik A. The effects of estrogen and progestins on blood pressure regulation of normotensive women. Am J Obstet Gynaecol 1971; 4:31-47.
72. Jesperson CM, Arnung K, Hagen C, et al. Effects of natural oestrogen therapy on blood pressure and the renin-angiotensin system in normotensive and hypertensive menopausal women. J Hypertens 1983; 1:361-4.
73. Sarrel PM. Effects of ovarian steroids on the cardiovascular system. In: Ginsburg J, ed. Circulation in the Female. Carnsforth, Parthenon Press, 1988:117-41.
74. Magness RR, Rosenfeld CR. Local and systemic estradiol-17: effects on uterine and systemic vasodilation. Am J Physiol 1989; 256:E536-42.
75. Rosenfeld CR, Morriss FH, Battaglia FC, Makowski FL, Meschia. Effect of oestradiol-17 on blood flow to reproductive and non-reproductive tissues in pregnant ewes. Am J Obstet Gynecol 1976; 124:618-29.
76. Williams JK, Admas MR, Klopfenstein HS. Estrogen modulates responses of atherosclerotic coronary arteries. Circulation 1990; 81:1680-7.
77. Bing RJ, Conforto A. Reversal of acetylcholine effect on atherosclerotic coronary arteries by estrogen; pharmacologic phenomenon of clinical importance? J Am Coll Cardiol 1992; 20:458-9.
78. Hammond CB, Jelvosek FR, Lee KL, et al. Effects of long-term estrogen therapy. Am J Obstet Gynecol 1979; 133:525-36.
79. Lafferty FW, Fiske ME. Postmenopausal estrogen replacement: a long-term cohort study. Am J Med 1004; 97:66-77.
80. Grady D, Rubia SM, Petitti DB, Fox CS, Black D, Ettinger B, Ernster VL, Cummings SR. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117:1016-37.
81. Grodstein F, Stampfer MJ, Colditz GA, Willett WC, Manson JAE, Joffe M, Rosner B, Fuchs C, Hankinson SE, Hunter DJ, Hennekens CH, Speizer FE. Postmenopausal hormone therapy and mortality. N Engl J Med 1997; 336:1769-75.
82. Bush TL, Barrett-Connor E, Cowan LD, Criqui MH, Wallace RB, Suchindran CM, Tyroler HA, Rifkind BM. Cardiovascular mortality and noncontraceptive use of oestrogen in women: results from the Lipid Research Clinics Program Follow-up study. Circulation 1987; 75:1102-9.
83. Wilson PWF, Garrison RJ, Castelli WP. Postmenopausal estrogen use, cigarette smoking and cardiovascular morbidity in women over 50. The Framingham Study. N Engl J Med 1985; 313:1038-43.
84. Grodstein F, Stampfer MJ, Manson JAE, Colditz GA, Willett WC, Rosner B, Speizer FE, Hennekens CH. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996; 335:453-61.
85. Cushman M, Legault C, Barrett-Connor E, Stefanick ML, Kessler C, Judd HL, Sakkinen PA, Tracey RP. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) study. In press. Authors please supply journal, etc.
86. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of Estrogen plus Progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 20:605-13.
87. Psaty BM, Heckbert SR, Atkins D, Lemaitre R, Koepsell TD, Wahl PW, Siscovick DS, Wagner EH. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. Arch Intern Med 1994; 154:1333-9.